AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04209959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifekalant
Description: Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
Study NCT00030498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00030498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01008319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Study NCT01008319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Study NCT03951077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule administered orally
Study NCT03951077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered orally
Study NCT03636217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-Milk Breakfast
Description: This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
Study NCT03636217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-Kefir Breakfast
Description: In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
Study NCT03636217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HGI-Kefir Breakfast
Description: In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
Study NCT01687361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branched-chain amino acids (BCAA) supplementation
Study NCT01687361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT01756768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]-PD-0332991
Description: A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
Study NCT01507519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Eluting Coronary Stent System (Biomime)
Description: Coronary Artey PTCA
Study NCT01183234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD544
Description: two 30mg capsules, single oral dose
Study NCT01183234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Description: one 60mg capsule, single oral dose
Study NCT03084341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Elongation
Description: Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
Study NCT00791388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule, 2x/day for 14 days
Study NCT00791388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 50 mg, 2x/day for 14 days
Study NCT00791388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 100mg, 2x/day for 14 days
Study NCT00791388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 200 mg, 2x/day for 14 days
Study NCT00791388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: oral capsule, 400 mg, 2x/day for 14 days
Study NCT03431441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Marketed Contact Lens
Description: Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
Study NCT02043938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SedLine EEG sensor
Description: Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
Study NCT03084341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
Study NCT02415673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed orthodontics appliance and arch wire
Description: Two nickel-titanium alignment and leveling sequences were employed
Study NCT04735328 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LOCI
Description: LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
Study NCT02471235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Pulmonary rehabilitation
Study NCT05005663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical management of incisional hernia
Description: surgical repair of the incisional hernia
Study NCT02222558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSX-002
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study NCT02305771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electroencephalography
Study NCT02305771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT03520985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression.
Study NCT03520985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~For patients > 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until confirmed disease progression.
Study NCT05288647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ injection
Description: four sodium hyaluronate injections in superior TMJ space
Study NCT05288647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ injection
Description: four sodium hyaluronate injections in superior TMJ space
Study NCT01115868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 5ng
Description: 100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
Study NCT01115868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 25ng
Description: • 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
Study NCT01115868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 100ng
Description: • 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
Study NCT01115868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevascar 250ng
Description: • 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
Study NCT04735328 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CT-PTSD
Description: CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
Study NCT04735328 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMDR
Description: EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT02178995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed.
Study NCT03318835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
Study NCT03318835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
Study NCT03315520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)
Study NCT01507688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self-Management
Description: Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
Study NCT04674007 — intervention group
Intervention type: OTHER
Intervention: 3D analysis of landing task
Description: Landing tasks (anticipated, unanticipated and cognitive dual task) are investigated with 3D analysis by using an opto-electronic system
Study NCT03726957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved Cookstoves
Description: Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
Study NCT02019732 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
Study NCT01544920 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peg-Interferon alfa-2a
Description: peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
Study NCT01544920 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-Interferon alfa-2a
Description: peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
Study NCT01544920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
Study NCT01544920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight \<75 kilograms \[kg\]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
Study NCT00363909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide
Study NCT01544920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
Study NCT01544920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
Study NCT03242694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LA pressure, voltage map, strain, scar-map, blood sampling
Description: invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
Study NCT03242694 — intervention group
Intervention type: PROCEDURE
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation without creating additional ablation lesions
Study NCT01412528 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Allergen extracts
Study NCT01648634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
Study NCT00363909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01473446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed fluid therapy guided by LiDCOrapid
Description: Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h.
Study NCT02488538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined oral contraceptives
Description: Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
Study NCT02488538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: women will receive oral fluoxetine 20 mg daily
Study NCT02488538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined oral contraceptives placebo
Description: women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
Study NCT02488538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine placebo
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
Study NCT02488538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine placebo
Description: women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
Study NCT01648634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
Study NCT00302341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pafuramidine maleate (DB289)
Description: Oral tablet, 100 mg bid, 14 days
Study NCT00302341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole (TMP-SMX)
Description: 15 mg/kg, oral tablet split tid X 21 days
Study NCT04499937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streak incentive
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with a $0 balance and will earn a fixed amount for each response.
Study NCT04499937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-based incentive
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will start with the maximum balance and will lose a fixed amount for each response they do not complete.
Study NCT04499937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flat-fee control status quo condition
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will receive the maximum compensation at the end of the study.
Study NCT04499937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flat-Fitbit control status quo condition
Description: Participants will receive prompts 3 times a day for 21 days prompting them to complete surveys. They will keep the Fitbit at the end of the study.
Study NCT02488538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Daily record of severity of problems
Description: Women will record their symptoms daily using the daily record of severity of symptoms.
Study NCT01765530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT cleaning maneuver
Description: EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period.
Study NCT00413556 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALK Grass tablet
Study NCT00413556 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALK Grass tablet
Study NCT02029937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine, high resolution imaging
Description: 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
Study NCT04007133 — intervention group
Intervention type: OTHER
Intervention: Girerd test
Description: This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
Study NCT02097290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D
Description: For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
Study NCT01654380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
Study NCT01654380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.